Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12206722 | 0.90 | HSD11B1 (0.41) | TSHRHPGDNPSR1HSD11B1NAMPT | |
| SCHEMBL30103443 | 0.82 | EPHX1 (0.40) | CXCR2NPSR1EPHX1NAMPTCNR2 | |
| SCHEMBL12282654 | 0.82 | EPHX1 (0.52) | HPGDEPHX1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12206723 | 0.82 | EPHX1 (0.47) | HPGDHSD11B1EPHX1DRD2NPC1 | |
| SCHEMBL12206725 | 0.82 | HSD11B1 (0.41) | TSHRHPGDHSD11B1EPHX1GRM5 | |
| SCHEMBL12206724 | 0.81 | HSD11B1 (0.42) | CXCR2TSHRHPGDNPSR1HSD11B1 | |
| SCHEMBL25480124 | 0.80 | EPHX1 (0.55) | HPGDNPSR1EPHX1NPC1RAB9A | |
| SCHEMBL19426127 | 0.80 | EPHX1 (0.55) | HPGDNPSR1EPHX1NPC1RAB9A | |
| SCHEMBL9357970 | 0.80 | EPHX1 (0.55) | HPGDNPSR1EPHX1NPC1RAB9A | |
| SCHEMBL25479961 | 0.80 | EPHX1 (0.55) | HPGDNPSR1EPHX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10590122-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10336746-B1 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190077799-A1 | RAD51 Inhibitors | CYTEIR THERAPEUTICS, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | CXCR2 2894/4885TSHR 3938/4885HPGD 2070/4885 |
| US-10590122-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | CXCR2 2542/4885TSHR 3630/4885HPGD 1959/4885 |
| US-10336746-B1 | RAD51 inhibitors | RAD51, MRE11, RAD54L | CXCR2 2542/4885TSHR 3630/4885HPGD 1959/4885 |
| US-20190077799-A1 | RAD51 Inhibitors | RAD51, MRE11, RAD54L | CXCR2 2542/4885TSHR 3630/4885HPGD 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.